Increasing Breast and Colorectal Cancer Screening in the Community
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Chi gung: Stay Well, Live Well, Chi gung: Stay Well, Live Well.
- Who it may be relevant to
- Registry conditions: Colorectal Neoplasms, Breast Neoplasms. Basic parameters: 45 years — 75 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Pilot Trial of a Community-Based Strategy to Improve Colorectal and Breast Cancer Screening
Overview
The goal of the proposed study is to conduct a pilot randomized controlled trial (RCT) of Chi gung, a community-based intervention using peer education and tailored navigation to simultaneously improve colorectal (CRC) and breast cancer (BC) screening rates.
Interventions
- Behavioral Chi gung: Stay Well, Live Well
The intervention consists of a A) 90-minute group education session led by a community health worker (CHW) that 1) addresses CRC and BC incidence, mortality, development, symptoms, and screening tests, in addition to shared beliefs and common obstacles to CRC and BC screening, 2) involves experiential education (e.g., demonstrations of stool based testing and colonoscopy bowel preparation), 3) question and answer session, and 4) take-home materials summarizing CRC and BC screening information an - Behavioral Chi gung: Stay Well, Live Well
The attention control arm will receive a A) time-matched (90-minute) general health didactic on risk factors for cancer and take-home materials on concepts discussed, and B) telephone calls to address concepts covered in the presentation (number of calls will be based on the average frequency of peer navigation calls in the intervention arm).
Primary outcome measures
- Intervention Acceptability Score [Time frame: 6 Months]
- Number of Navigation Calls [Time frame: 6 Months]
- Intervention Adaptation Score [Time frame: Baseline, Immediately Post-Education Session, 6 Months]
- The Proportion of Participants Who Have Completed Recommended Screening Tests. [Time frame: 6 Months]
Eligibility criteria
Inclusion criteria
- Age 45-75 years old
- Self-identify as Chinese and born outside of the U.S.
- Speaks Mandarin, Cantonese, or English
- Not up to date on BC screening (i.e., have not had a mammogram within the past two years)
- Not up to date on CRC screening (i.e., have not had any of the following tests)
- Colonoscopy within the past 10 years
- Fecal immunochemical tests/fecal occult blood tests within the past year or multi-target stool DNA test within the past three years
- Flexible sigmoidoscopy within the past 5 years
- CT colonography within the past 5 years
Exclusion criteria
- Life expectancy ≤ 10 years or other pre-existing conditions whereby CRC or BC screening would not be recommended
- Personal history of BC or CRC
- Prior history of a total colectomy or mastectomy
- Lacks capacity to provide informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Prevention
Study locations
United States · 7 centers
- Henry Street Settlement — New York
- University Settlement — New York
- Charles B. Wang Community Health Center — New York
- VNS Health Chinatown Community Center — New York
- The Icahn School of Medicine at Mount Sinai — New York
- St. Margaret's House — New York
- United Chinese Association of Brooklyn — New York
Identifiers
NCT: NCT07748377 · STUDY-23-01343 · K08CA283362